You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 202224012
Nov 202244014
Dec 202252015
Jan 20231902
Feb 20232700
Mar 20231706
Apr 20231201
May 20231403
Jun 20231406
Jul 20231203
Aug 20231405
Sep 2023803
Oct 20231103
Nov 20231203
Dec 20231703
Jan 20241202
Feb 20242803
Mar 20241700
Apr 20241803
May 2024802
Jun 20241003
Jul 2024002
Aug 2024502
Sep 20241101
Oct 2024400
Total410097